Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>

Saved in:

Bibliographic Details
Main Author:	Amir T. Fathi (15313195) (author)
Other Authors:	Haesook T. Kim (15313198) (author), Robert J. Soiffer (15313201) (author), Mark J. Levis (15313204) (author), Shuli Li (15313207) (author), Annette S. Kim (15117505) (author), Zachariah DeFilipp (15313210) (author), Areej El-Jawahri (15313213) (author), Steve L. McAfee (15313216) (author), Andrew M. Brunner (15313219) (author), Philip C. Amrein (15313222) (author), Alice S. Mims (11016414) (author), Laura W. Knight (15313225) (author), Devon Kelley (15313228) (author), AJ S. Bottoms (15313231) (author), Lindsey H. Perry (15313234) (author), Jonathan L. Wahl (15313237) (author), Jennifer Brock (15313240) (author), Elayne Breton (15313243) (author), Dylan M. Marchione (14935655) (author), Vincent T. Ho (15313246) (author), Yi-Bin Chen (15313249) (author)
Published:	2025
Subjects:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Hematological Cancers Leukemias Immunotherapy Stem cell transplantation
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items